Nov. 20, 2013
(NASDAQ: MBLX), an innovation-driven performance biomaterials company delivering sustainable solutions to the plastics, chemicals and energy industries, today announced that Chief Scientific Officer
, Ph.D. will present the Company's strategy for its polyhydroxyalkanoate (PHA)-based biopolymers and biobased chemicals platform. This presentation will include new data on the successful conversion of second generation cellulosic sugars to PHA precursors for the production of PHA biopolymers and biobased chemicals, including C3 (bio-acrylic) and C4 chemicals.
Dr. Peoples' presentation at the
is scheduled for
Thursday, November 21
4:15 p.m. (CET)
. The data presented by Dr. Peoples will demonstrate for the first time that microbes designed by Metabolix researchers can produce targeted PHAs through fermentation at a virtually identical growth rate and yield using cellulosic sugars as feedstock as compared to using first generation corn-based industrial sugar. This data highlights the robust nature of the microbial strains engineered by Metabolix, and the potential to use alternative, renewable feedstocks for conversion in commercial scale fermentation.
"The findings we will report suggest that our microbial strains for producing biopolymers and biobased chemicals are extremely robust and flexible on the feedstocks they can use. Even without any additional genetic modification, the Company's production organisms can effectively use second generation cellulosic sugar as a feedstock," said Dr. Peoples. "The significance of this finding is that it is now clear that our PHA technology provides us with the flexibility to use a range of first generation industrial sugars, as well as second generation cellulosic sugars, and in the long-term gives us another way to manage the cost of raw material inputs."